DRMA (Dermata Therapeutics) Tariff Resilience Score: 4/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DRMA Dermata Therapeutics Inc DRMA
22 GF Score
Price $1.24
! 2 Warning Signs
View Full Analysis

What is Dermata Therapeutics Tariff Resilience Score?

Dermata Therapeutics DRMA -4.26% 22 Tariff Resilience Score is 4 as of Jul. 28, 2026. GuruFocus rates DRMA with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,367 Biotechnology companies, Dermata Therapeutics ranks better than 52.52% on this metric.

Dermata Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Dermata Therapeutics has Dermata Therapeutics is vulnerable due to reliance on international suppliers for raw materials. The biotech industry faces specific tariff challenges, and previous changes have impacted costs. Limited pricing power and few alternative suppliers increase vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Dermata Therapeutics might have Average Resilient.

Dermata Therapeutics  (NAS:DRMA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Dermata Therapeutics Tariff Resilience Score Related Terms

DRMA vs CURX, CELZ, NCNA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Dermata Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermata Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's Tariff Resilience Score falls into.


DRMA
22GF Score
Dermata Therapeutics Inc DRMA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Dermata Therapeutics (DRMA) has a Tariff Resilience Score of 4 as of Jul. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Dermata Therapeutics ranks #649 out of 1367 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Dermata Therapeutics' Tariff Resilience Score too high?
Dermata Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Dermata Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Dermata Therapeutics ranks #649 out of 1367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dermata Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Dermata Therapeutics' Tariff Resilience Score compare to CURX and CELZ?
According to the Biotechnology industry distribution chart, Dermata Therapeutics ranks #649 out of 1367 companies for Tariff Resilience Score. This puts Dermata Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Dermata Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermata Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermata Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermata Therapeutics stock overvalued right now?
Dermata Therapeutics (DRMA) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Dermata Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Dermata Therapeutics (DRMA), the current Tariff Resilience Score is 4 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dermata Therapeutics Business Description

Address 3525 Del Mar Heights Road, No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
22GF Score

Get the complete analysis for DRMA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price